In a trial, sotagliflozin use in patients with diabetes and chronic kidney disease (CKD) was associated with lower risk of ischemic cardiovascular outcomes.

The dual sodium-glucose cotransporter 1 and 2 (SGLT1/2) inhibitor sotagliflozin reduced major adverse cardiovascular events, with significant reductions in the individual outcomes of myocardial ...

The dual SGLT1/2 inhibitor yielded a 32% reduction in myocardial infarction risk and 34% reduction in stroke risk. It's first SGLT inhibitor to provide a significant reduction in both myocardial ...

Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help ...

Sotagliflozin is a sodium-glucose cotransporter (SGLT) inhibitor. It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help ...

Neither of the selective SGLT2 inhibitors have yet been shown to reduce MI and stroke events. Sotagliflozin, however, inhibits SGLT2 as well as gastrointestinal SGLT1; the latter effect, the study ...

Medscape News UK, February 27, 2025 Dual SGLT1/2 Inhibitor Protects Against MI and Stroke Sotagliflozin, a dual SGLT1/2 inhibitor, reduces cardiovascular events in people with diabetic kidney ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and ...

New research shows sotagliflozin is the only drug in its class to demonstrate these results. Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes ...